Matches in Nanopublications for { ?s ?p "IGFbPs limit IGF access to IGF1R, thereby attenuating the bioactivity of these growth factors33. The tumour suppressor p53 (REF. 34), as well as many growth inhibitors including vitamin d35, anti- oestrogens36, retinoids37, and transforming growth factor-? (TGF?37), reduce IGF bioactivity by increasing the secretion of IGFbPs33." ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- _5 value "IGFbPs limit IGF access to IGF1R, thereby attenuating the bioactivity of these growth factors33. The tumour suppressor p53 (REF. 34), as well as many growth inhibitors including vitamin d35, anti- oestrogens36, retinoids37, and transforming growth factor-? (TGF?37), reduce IGF bioactivity by increasing the secretion of IGFbPs33." provenance.
- _4 value "IGFbPs limit IGF access to IGF1R, thereby attenuating the bioactivity of these growth factors33. The tumour suppressor p53 (REF. 34), as well as many growth inhibitors including vitamin d35, anti- oestrogens36, retinoids37, and transforming growth factor-? (TGF?37), reduce IGF bioactivity by increasing the secretion of IGFbPs33." provenance.
- _5 value "IGFbPs limit IGF access to IGF1R, thereby attenuating the bioactivity of these growth factors33. The tumour suppressor p53 (REF. 34), as well as many growth inhibitors including vitamin d35, anti- oestrogens36, retinoids37, and transforming growth factor-? (TGF?37), reduce IGF bioactivity by increasing the secretion of IGFbPs33." provenance.
- _4 value "IGFbPs limit IGF access to IGF1R, thereby attenuating the bioactivity of these growth factors33. The tumour suppressor p53 (REF. 34), as well as many growth inhibitors including vitamin d35, anti- oestrogens36, retinoids37, and transforming growth factor-? (TGF?37), reduce IGF bioactivity by increasing the secretion of IGFbPs33." provenance.